Beta-variant recombinant SARS CoV-2 vaccine induces durable cross-reactive antibodies against Omicron BA variants
Abstract Background We previously reported the safety and immunogenicity data from a randomized trial comparing the booster responses of vaccinees who received monovalent (MV) recombinant protein Beta-variant (MVB.1.351) and MV ancestral protein (MVD614) vaccines with AS03 adjuvant (Sanofi/GSK) to b...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Communications Medicine |
| Online Access: | https://doi.org/10.1038/s43856-024-00675-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594504852439040 |
|---|---|
| author | Odile Launay Rachna Gupta Tifany Machabert Eleine Konate Alexandra Rousseau Claire Vigne Francois Beckers Louis Devlin Elisabeth Botelho-Nevers Marine Cachanado Christian Chidiac Dominique Deplanque Bertrand Dussol Inès Ben Ghezala Marie Lachatre Karine Lacombe Fabrice Laine Liem Binh Luong Nguyen Patricia Pavese Catherine Schmidt-Mutter Marie-Pierre Tavolacci Roman M. Chicz Bogdana Coudsy Saranya Sridhar Amel Touati Eric Tartour Tabassome Simon |
| author_facet | Odile Launay Rachna Gupta Tifany Machabert Eleine Konate Alexandra Rousseau Claire Vigne Francois Beckers Louis Devlin Elisabeth Botelho-Nevers Marine Cachanado Christian Chidiac Dominique Deplanque Bertrand Dussol Inès Ben Ghezala Marie Lachatre Karine Lacombe Fabrice Laine Liem Binh Luong Nguyen Patricia Pavese Catherine Schmidt-Mutter Marie-Pierre Tavolacci Roman M. Chicz Bogdana Coudsy Saranya Sridhar Amel Touati Eric Tartour Tabassome Simon |
| author_sort | Odile Launay |
| collection | DOAJ |
| description | Abstract Background We previously reported the safety and immunogenicity data from a randomized trial comparing the booster responses of vaccinees who received monovalent (MV) recombinant protein Beta-variant (MVB.1.351) and MV ancestral protein (MVD614) vaccines with AS03 adjuvant (Sanofi/GSK) to booster response of vaccinees who received mRNA MV ancestral strain BNT162b2 vaccine (Pfizer-BioNTech). Methods First booster of the vaccines was administered in adult participants previously primed with 2 doses of MV ancestral strain BNT162b2. A subset of these participants with available blood samples collected at Day 0 (D0), at 28 days (D28), and 3 months (M3) post-booster were contacted for additional testing (195/208 participants). The persistence of cross-neutralizing antibodies, including against Omicron BA.1 and BA.4/5, up to 3 months after boosting was evaluated using a validated pseudovirus neutralization assay. Results Across the whole population, MVB.1.351 vaccine induces highest NAbs titers against Omicron BA.1 and BA.4/5 variants at D28 and M3 post-booster. In participants with SARS-CoV-2 infection between D28 and M3, both MVB.1.351 and BNT162b2 vaccine groups show an increase in GMTs against Omicron BA.1 and Omicron BA.4/5 following infection. Among uninfected participants, the ratio of M3 to D28 GMTs was higher for the MVB.1.351 group than the BNT162b2 group against Omicron BA.1 (0.64 [0.53;0.77] versus 0.43 [0.35;0.53]), Omicron BA.4/5 (0.61 [0.50; 0.75] versus 0.44 [0.34; 0.56]), and D614 (0.68 [0.58,0.81] versus 0.46 [0.39,0.55]). Conclusions The MVB.1.351 vaccine induces higher and durable cross-neutralizing antibodies against Omicron subvariants up to 3 months after boosting compared to an MV ancestral and mRNA BNT162b2 booster vaccine. |
| format | Article |
| id | doaj-art-b7a0670298594143ae1b61b05886a1e8 |
| institution | Kabale University |
| issn | 2730-664X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Communications Medicine |
| spelling | doaj-art-b7a0670298594143ae1b61b05886a1e82025-01-19T12:36:58ZengNature PortfolioCommunications Medicine2730-664X2025-01-01511710.1038/s43856-024-00675-9Beta-variant recombinant SARS CoV-2 vaccine induces durable cross-reactive antibodies against Omicron BA variantsOdile Launay0Rachna Gupta1Tifany Machabert2Eleine Konate3Alexandra Rousseau4Claire Vigne5Francois Beckers6Louis Devlin7Elisabeth Botelho-Nevers8Marine Cachanado9Christian Chidiac10Dominique Deplanque11Bertrand Dussol12Inès Ben Ghezala13Marie Lachatre14Karine Lacombe15Fabrice Laine16Liem Binh Luong Nguyen17Patricia Pavese18Catherine Schmidt-Mutter19Marie-Pierre Tavolacci20Roman M. Chicz21Bogdana Coudsy22Saranya Sridhar23Amel Touati24Eric Tartour25Tabassome Simon26Assistance Publique Hôpitaux Paris (APHP), Hôpital Cochin; Université Paris Cité; Inserm CIC 1417 Cochin PasteurSanofiSanofiAssistance Publique Hôpitaux Paris (APHP), Hôpital Cochin; Université Paris Cité; Inserm CIC 1417 Cochin PasteurAPHP, Hôpital Saint Antoine, Unité de Recherche Clinique (URCEST), Centre de Ressources Biologiques (CRB)SanofiSanofiSanofiService d’infectiologie, CIC1408, Inserm, CHU de Saint-EtienneAPHP, Hôpital Saint Antoine, Unité de Recherche Clinique (URCEST), Centre de Ressources Biologiques (CRB)Maladies Infectieuses, GHN Croix Rousse, Hospices Civils de LyonUniv. Lille, Inserm, CHU Lille, CIC 1403 - Centre d’Investigation CliniqueCIC 14-09, INSERM - Aix Marseille Université – Hôpitaux Universitaires de MarseilleInserm, CIC 1432, Clinical Investigation Center, Clinical Epidemiology/Clinical Trials Unit, University HospitalAssistance Publique Hôpitaux Paris (APHP), Hôpital Cochin; Université Paris Cité; Inserm CIC 1417 Cochin PasteurSorbonne Université, IPLESP Inserm UMR-S1136, Hôpital St Antoine AP-HPINSERM, CIC 1414, CHU RennesAssistance Publique Hôpitaux Paris (APHP), Hôpital Cochin; Université Paris Cité; Inserm CIC 1417 Cochin PasteurMaladies Infectieuses et Tropicales, CHU de Grenoble AlpesInserm CIC 1434, CHU StrasbourgUniversité Rouen, Inserm 1073, CHU Rouen, CIC 1404 - Centre d’investigation cliniqueSanofiSanofiSanofiAPHP, Hôpital Saint Antoine, Unité de Recherche Clinique (URCEST), Centre de Ressources Biologiques (CRB)APHP, Hôpital Européen Georges Pompidou; PARCC, INSERM U970 Université de ParisURC EST, Sorbonne UniversitéAbstract Background We previously reported the safety and immunogenicity data from a randomized trial comparing the booster responses of vaccinees who received monovalent (MV) recombinant protein Beta-variant (MVB.1.351) and MV ancestral protein (MVD614) vaccines with AS03 adjuvant (Sanofi/GSK) to booster response of vaccinees who received mRNA MV ancestral strain BNT162b2 vaccine (Pfizer-BioNTech). Methods First booster of the vaccines was administered in adult participants previously primed with 2 doses of MV ancestral strain BNT162b2. A subset of these participants with available blood samples collected at Day 0 (D0), at 28 days (D28), and 3 months (M3) post-booster were contacted for additional testing (195/208 participants). The persistence of cross-neutralizing antibodies, including against Omicron BA.1 and BA.4/5, up to 3 months after boosting was evaluated using a validated pseudovirus neutralization assay. Results Across the whole population, MVB.1.351 vaccine induces highest NAbs titers against Omicron BA.1 and BA.4/5 variants at D28 and M3 post-booster. In participants with SARS-CoV-2 infection between D28 and M3, both MVB.1.351 and BNT162b2 vaccine groups show an increase in GMTs against Omicron BA.1 and Omicron BA.4/5 following infection. Among uninfected participants, the ratio of M3 to D28 GMTs was higher for the MVB.1.351 group than the BNT162b2 group against Omicron BA.1 (0.64 [0.53;0.77] versus 0.43 [0.35;0.53]), Omicron BA.4/5 (0.61 [0.50; 0.75] versus 0.44 [0.34; 0.56]), and D614 (0.68 [0.58,0.81] versus 0.46 [0.39,0.55]). Conclusions The MVB.1.351 vaccine induces higher and durable cross-neutralizing antibodies against Omicron subvariants up to 3 months after boosting compared to an MV ancestral and mRNA BNT162b2 booster vaccine.https://doi.org/10.1038/s43856-024-00675-9 |
| spellingShingle | Odile Launay Rachna Gupta Tifany Machabert Eleine Konate Alexandra Rousseau Claire Vigne Francois Beckers Louis Devlin Elisabeth Botelho-Nevers Marine Cachanado Christian Chidiac Dominique Deplanque Bertrand Dussol Inès Ben Ghezala Marie Lachatre Karine Lacombe Fabrice Laine Liem Binh Luong Nguyen Patricia Pavese Catherine Schmidt-Mutter Marie-Pierre Tavolacci Roman M. Chicz Bogdana Coudsy Saranya Sridhar Amel Touati Eric Tartour Tabassome Simon Beta-variant recombinant SARS CoV-2 vaccine induces durable cross-reactive antibodies against Omicron BA variants Communications Medicine |
| title | Beta-variant recombinant SARS CoV-2 vaccine induces durable cross-reactive antibodies against Omicron BA variants |
| title_full | Beta-variant recombinant SARS CoV-2 vaccine induces durable cross-reactive antibodies against Omicron BA variants |
| title_fullStr | Beta-variant recombinant SARS CoV-2 vaccine induces durable cross-reactive antibodies against Omicron BA variants |
| title_full_unstemmed | Beta-variant recombinant SARS CoV-2 vaccine induces durable cross-reactive antibodies against Omicron BA variants |
| title_short | Beta-variant recombinant SARS CoV-2 vaccine induces durable cross-reactive antibodies against Omicron BA variants |
| title_sort | beta variant recombinant sars cov 2 vaccine induces durable cross reactive antibodies against omicron ba variants |
| url | https://doi.org/10.1038/s43856-024-00675-9 |
| work_keys_str_mv | AT odilelaunay betavariantrecombinantsarscov2vaccineinducesdurablecrossreactiveantibodiesagainstomicronbavariants AT rachnagupta betavariantrecombinantsarscov2vaccineinducesdurablecrossreactiveantibodiesagainstomicronbavariants AT tifanymachabert betavariantrecombinantsarscov2vaccineinducesdurablecrossreactiveantibodiesagainstomicronbavariants AT eleinekonate betavariantrecombinantsarscov2vaccineinducesdurablecrossreactiveantibodiesagainstomicronbavariants AT alexandrarousseau betavariantrecombinantsarscov2vaccineinducesdurablecrossreactiveantibodiesagainstomicronbavariants AT clairevigne betavariantrecombinantsarscov2vaccineinducesdurablecrossreactiveantibodiesagainstomicronbavariants AT francoisbeckers betavariantrecombinantsarscov2vaccineinducesdurablecrossreactiveantibodiesagainstomicronbavariants AT louisdevlin betavariantrecombinantsarscov2vaccineinducesdurablecrossreactiveantibodiesagainstomicronbavariants AT elisabethbotelhonevers betavariantrecombinantsarscov2vaccineinducesdurablecrossreactiveantibodiesagainstomicronbavariants AT marinecachanado betavariantrecombinantsarscov2vaccineinducesdurablecrossreactiveantibodiesagainstomicronbavariants AT christianchidiac betavariantrecombinantsarscov2vaccineinducesdurablecrossreactiveantibodiesagainstomicronbavariants AT dominiquedeplanque betavariantrecombinantsarscov2vaccineinducesdurablecrossreactiveantibodiesagainstomicronbavariants AT bertranddussol betavariantrecombinantsarscov2vaccineinducesdurablecrossreactiveantibodiesagainstomicronbavariants AT inesbenghezala betavariantrecombinantsarscov2vaccineinducesdurablecrossreactiveantibodiesagainstomicronbavariants AT marielachatre betavariantrecombinantsarscov2vaccineinducesdurablecrossreactiveantibodiesagainstomicronbavariants AT karinelacombe betavariantrecombinantsarscov2vaccineinducesdurablecrossreactiveantibodiesagainstomicronbavariants AT fabricelaine betavariantrecombinantsarscov2vaccineinducesdurablecrossreactiveantibodiesagainstomicronbavariants AT liembinhluongnguyen betavariantrecombinantsarscov2vaccineinducesdurablecrossreactiveantibodiesagainstomicronbavariants AT patriciapavese betavariantrecombinantsarscov2vaccineinducesdurablecrossreactiveantibodiesagainstomicronbavariants AT catherineschmidtmutter betavariantrecombinantsarscov2vaccineinducesdurablecrossreactiveantibodiesagainstomicronbavariants AT mariepierretavolacci betavariantrecombinantsarscov2vaccineinducesdurablecrossreactiveantibodiesagainstomicronbavariants AT romanmchicz betavariantrecombinantsarscov2vaccineinducesdurablecrossreactiveantibodiesagainstomicronbavariants AT bogdanacoudsy betavariantrecombinantsarscov2vaccineinducesdurablecrossreactiveantibodiesagainstomicronbavariants AT saranyasridhar betavariantrecombinantsarscov2vaccineinducesdurablecrossreactiveantibodiesagainstomicronbavariants AT ameltouati betavariantrecombinantsarscov2vaccineinducesdurablecrossreactiveantibodiesagainstomicronbavariants AT erictartour betavariantrecombinantsarscov2vaccineinducesdurablecrossreactiveantibodiesagainstomicronbavariants AT tabassomesimon betavariantrecombinantsarscov2vaccineinducesdurablecrossreactiveantibodiesagainstomicronbavariants |